|
1
|
Bray F, Laversanne M, Sung H, Ferlay J,
Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics
2022: GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin. 74:229–263.
2024.PubMed/NCBI View Article : Google Scholar
|
|
2
|
National Cancer Registry, Ministry of
Health, Labour and Welfare Cancer Statistics: Cancer Information
Service, National Cancer Center, Japan. https://ganjoho.jp/reg_stat/statistics/data/dl/index.html.
Accessed on April 1, 2024.
|
|
3
|
SEER 5-year relative survival rate,
2012-2018. Cancer Statistics Explorer Network, National Cancer
Institute, United States. https://seer.cancer.gov/statistics-network/explorer/application.html.
Accessed on April 1, 2024.
|
|
4
|
NCCN Clinical Practice Guidelines in
Oncology; Gastric Cancer Version 1.2024. https://www.nccn.org/guidelines/category_1. Accessed
April 1, 2024.
|
|
5
|
Japanese Gastric Cancer Association.
Japanese gastric cancer treatment guidelines 2021 (6th edition).
Gastric Cancer. 26:1–25. 2023.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Kang YK, Boku N, Satoh T, Ryu MH, Chao Y,
Kato K, Chung HC, Chen JS, Muro K, Kang WK, et al: Nivolumab in
patients with advanced gastric or gastro-oesophageal junction
cancer refractory to, or intolerant of, at least two previous
chemotherapy regimens (ONO-4538-12, ATTRACTION-2): A randomised,
double-blind, placebo-controlled, phase 3 trial. Lancet.
390:2461–2471. 2017.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Japanese Gastric Cancer Association.
Japanese gastric cancer treatment guidelines 2018 (5th edition).
Gastric Cancer. 24:1–21. 2021.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Shitara K, Doi T, Dvorkin M, Mansoor W,
Arkenau HT, Prokharau A, Alsina M, Ghidini M, Faustino C, Gorbunova
V, et al: Trifluridine/tipiracil versus placebo in patients with
heavily pretreated metastatic gastric cancer (TAGS): A randomised,
double-blind, placebo-controlled, phase 3 trial. Lancet Oncol.
19:1437–1448. 2018.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Janjigian YY, Shitara K, Moehler M,
Garrido M, Salman P, Shen L, Wyrwicz L, Yamaguchi K, Skoczylas T,
Bragagnoli AC, et al: First-line nivolumab plus chemotherapy versus
chemotherapy alone for advanced gastric, gastro-oesophageal
junction, and oesophageal adenocarcinoma (CheckMate 649): A
randomised, open-label, phase 3 trial. Lancet. 398:27–40.
2021.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Kang YK, Chen LT, Ryu MH, Oh DY, Oh SC,
Chung HC, Lee KW, Omori T, Shitara K, Sakuramoto S, et al:
Nivolumab plus chemotherapy versus placebo plus chemotherapy in
patients with HER2-negative, untreated, unresectable advanced or
recurrent gastric or gastro-oesophageal junction cancer
(ATTRACTION-4): A randomised, multicentre, double-blind,
placebo-controlled, phase 3 trial. Lancet Oncol. 23:234–247.
2022.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Ricci AD, Rizzo A and Brandi G: DNA damage
response alterations in gastric cancer: Knocking down a new wall.
Future Oncol. 7:865–868. 2021.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Marabelle A, Le DT, Ascierto PA, Di
Giacomo AM, De Jesus-Acosta A, Delord JP, Geva R, Gottfried M,
Penel N, Hansen AR, et al: Efficacy of pembrolizumab in patients
with noncolorectal high microsatellite Instability/Mismatch
repair-deficient cancer: Results from the phase II KEYNOTE-158
study. J Clin Oncol. 38:1–10. 2020.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Marabelle A, Fakih M, Lopez J, Shah M,
Shapira-Frommer R, Nakagawa K, Chung HC, Kindler HL, Lopez-Martin
JA, Miller WH Jr, et al: Association of tumour mutational burden
with outcomes in patients with advanced solid tumours treated with
pembrolizumab: Prospective biomarker analysis of the multicohort,
open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 21:1353–1365.
2020.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Akagi K, Oki E, Taniguchi H, Nakatani K,
Aoki D, Kuwata T and Yoshino T: Real-world data on microsatellite
instability status in various unresectable or metastatic solid
tumors. Cancer Sci. 112:1105–1113. 2021.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Parikh AR, He Y, Hong TS, Corcoran RB,
Clark JW, Ryan DP, Zou L, Ting DT, Catenacci DV, Chao J, et al:
Analysis of DNA damage response gene alterations and tumor
mutational burden across 17,486 tubular gastrointestinal
carcinomas: Implications for therapy. Oncologist. 24:1340–1347.
2019.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Rihawi K, Ricci AD, Rizzo A, Brocchi S,
Marasco G, Pastore LV, Llimpe FLR, Golfieri R and Renzulli M:
Tumor-associated macrophages and inflammatory microenvironment in
gastric cancer: Novel translational implications. Int J Mol Sci.
22(3805)2021.PubMed/NCBI View Article : Google Scholar
|
|
17
|
McMillan DC: Systemic inflammation,
nutritional status and survival in patients with cancer. Curr Opin
Clin Nutr Metab Care. 12:223–226. 2009.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Dolan RD, Lim J, McSorley ST, Horgan PG,
Laird B and McMillan DC: The role of the systemic inflammatory
response in predicting outcomes in patients with advanced
inoperable cancer: Systematic review and meta-analysis. Crit Rev
Oncol Hematol. 116:134–146. 2017.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Guven DC, Sahin TK, Erul E, Rizzo A, Ricci
AD, Aksoy S and Yalcin S: The association between albumin levels
and survival in patients treated with immune checkpoint inhibitors:
A systematic review and meta-analysis. Front Mol Biosci.
9(1039121)2022.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Zhang Y, Chen S, Chen H and Li W: A
comprehensive analysis of Glasgow prognostic score (GPS)/the
modified Glasgow prognostic score (mGPS) on immune checkpoint
inhibitor efficacy among patients with advanced cancer. Cancer Med.
12:38–48. 2023.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Chen J, Wei S, Zhao T and Zhang X, Wang Y
and Zhang X: Clinical significance of serum biomarkers in stage IV
non-small-cell lung cancer treated with PD-1 inhibitors: LIPI
Score, NLR, dNLR, LMR, and PAB. Dis Markers.
2022(7137357)2022.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Tanaka S, Uchino J, Yokoi T, Kijima T,
Goto Y, Suga Y, Katayama Y, Nakamura R, Morimoto K, Nakao A, et al:
Prognostic nutritional index and lung immune prognostic index as
prognostic predictors for combination therapies of immune
checkpoint inhibitors and cytotoxic anticancer chemotherapy for
patients with advanced non-small cell lung cancer. Diagnostics
(Basel). 12(423)2022.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Onodera T, Goseki N and Kosaki G:
Prognostic nutritional index in gastrointestinal surgery of
malnourished cancer patients. Nihon Geka Gakkai Zasshi.
85:1001–1005. 1984.PubMed/NCBI(In Japanese).
|
|
24
|
Forrest LM, McMillan DC, McArdle CS,
Angerson WJ and Dunlop DJ: Evaluation of cumulative prognostic
scores based on the systemic inflammatory response in patients with
inoperable non-small-cell lung cancer. Br J Cancer. 89:1028–1030.
2003.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Toiyama Y, Miki C, Inoue Y, Tanaka K,
Mohri Y and Kusunoki M: Evaluation of an inflammation-based
prognostic score for the identification of patients requiring
postoperative adjuvant chemotherapy for stage II colorectal cancer.
Exp Ther Med. 2:95–101. 2011.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Fairclough E, Cairns E, Hamilton J and
Kelly C: Evaluation of a modified early warning system for acute
medical admissions and comparison with C-reactive protein/albumin
ratio as a predictor of patient outcome. Clin Med (Lond). 9:30–33.
2009.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Nakahara K, Monden Y, Ohno K, Fujii Y,
Hashimoto J, Kitagawa Y and Kawashima Y: Importance of biologic
status to the postoperative prognosis of patients with stage III
nonsmall cell lung cancer. J Surg Oncol. 36:155–160.
1987.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Smith RA, Bosonnet L, Raraty M, Sutton R,
Neoptolemos JP, Campbell F and Ghaneh P: Preoperative
platelet-lymphocyte ratio is an independent significant prognostic
marker in resected pancreatic ductal adenocarcinoma. Am J Surg.
197:466–472. 2009.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Wilcox RA, Ristow K, Habermann TM, Inwards
DJ, Micallef IN, Johnston PB, Colgan JP, Nowakowski GS, Ansell SM,
Witzig TE, et al: The absolute monocyte and lymphocyte prognostic
score predicts survival and identifies high-risk patients in
diffuse large-B-cell lymphoma. Leukemia. 25:1502–1509.
2011.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Proctor MJ, McMillan DC, Morrison DS,
Fletcher CD, Horgan PG and Clarke SJ: A derived neutrophil to
lymphocyte ratio predicts survival in patients with cancer. Br J
Cancer. 107:695–699. 2012.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Watt DG, Proctor MJ, Park JH, Horgan PG
and McMillan DC: The neutrophil-platelet score (NPS) predicts
survival in primary operable colorectal cancer and a variety of
common cancers. PLoS One. 10(e0142159)2015.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Dolan RD, McSorley ST, Park JH, Watt DG,
Roxburgh CS, Horgan PG and McMillan DC: The prognostic value of
systemic inflammation in patients undergoing surgery for colon
cancer: Comparison of composite ratios and cumulative scores. Br J
Cancer. 119:40–51. 2018.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Dolan RD, Alwahid M, McSorley ST, Park JH,
Stevenson RP, Roxburgh CS, Horgan PG and McMillan DC: A comparison
of the prognostic value of composite ratios and cumulative scores
in patients with operable rectal cancer. Sci Rep.
10(17965)2020.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Kasymjanova G, MacDonald N, Agulnik JS,
Cohen V, Pepe C, Kreisman H, Sharma R and Small D: The predictive
value of pre-treatment inflammatory markers in advanced
non-small-cell lung cancer. Curr Oncol. 17:52–58. 2010.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Hu B, Yang XR, Xu Y, Sun YF, Sun C, Guo W,
Zhang X, Wang WM, Qiu SJ, Zhou J and Fan J: Systemic
immune-inflammation index predicts prognosis of patients after
curative resection for hepatocellular carcinoma. Clin Cancer Res.
20:6212–6222. 2014.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Qi Q, Zhuang L, Shen Y, Geng Y, Yu S, Chen
H, Liu L, Meng Z, Wang P and Chen Z: A novel systemic inflammation
response index (SIRI) for predicting the survival of patients with
pancreatic cancer after chemotherapy. Cancer. 122:2158–2167.
2016.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Mezquita L, Auclin E, Ferrara R, Charrier
M, Remon J, Planchard D, Ponce S, Ares LP, Leroy L,
Audigier-Valette C, et al: Association of the lung immune
prognostic index with immune checkpoint inhibitor outcomes in
patients with advanced non-small cell lung cancer. JAMA Oncol.
4:351–357. 2018.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Müller L, Hahn F, Mähringer-Kunz A, Stoehr
F, Gairing SJ, Michel M, Foerster F, Weinmann A, Galle PR, Mittler
J, et al: Immunonutritive scoring for patients with hepatocellular
carcinoma undergoing transarterial chemoembolization: Evaluation of
the CALLY index. Cancers (Basel). 13(5018)2021.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Averitt AJ, Weng C, Ryan P and Perotte A:
Translating evidence into practice: Eligibility criteria fail to
eliminate clinically significant differences between real-world and
study populations. NPJ Digit Med. 3(67)2020.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Hilgers RD, König F, Molenberghs G and
Senn S: Design and analysis of clinical trials for small rare
disease populations. J Rare Dis Res Treat. 1:53–60. 2016.
|
|
41
|
Latimer NR: Survival analysis for economic
evaluations alongside clinical trials-extrapolation with
patient-level data: Inconsistencies, limitations, a practice guide.
Med Decis Making. 33:743–754. 2013.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Corrigan-Curay J, Sacks L and Woodcock J:
Real-word evidence and real-world data for evaluating drug safety
and effectiveness. JAMA. 320:867–868. 2018.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Katkade VB, Sanders KN and Zou KH: Real
world data: An opportunity to supplement existing evidence for the
use of long-established medicines in health care decision making. J
Multidiscip Healthc. 11:295–304. 2018.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Makady A, de Boer A, Hillege H, Klungel O
and Goettsch W: (on behalf of GetReal Work Package 1). What is
real-world data? A review of definitions based on literature and
stakeholder interviews. Value Health. 20:858–865. 2017.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Shimoyama R, Imamura Y, Uryu K, Mase T,
Fujimura Y, Hayashi M, Ohtaki M, Ohtani K, Shinozaki N and Minami
H: Real-world outcomes of systemic therapy in Japanese patients
with cancer (Tokushukai REAl-World Data Project: TREAD): Study
protocol for a nationwide cohort study. Healthcare (Basel).
10(2146)2022.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Eba J and Nakamura K: Overview of the
ethical guidelines for medical and biological research involving
human subjects in Japan. Jpn J Clin Oncol. 52:539–544.
2022.PubMed/NCBI View Article : Google Scholar
|
|
47
|
National Cancer Registry (Ministry of
Health, Labour and Welfare), tabulated by Cancer Information
Service, National Cancer Center, Japan. https://ganjoho.jp/reg_stat/statistics/data/dl/en.html.
(Accessed 1 April 2024).
|
|
48
|
Shimoyama R, Imamura Y, Uryu K, Mase T,
Shiragami M, Fujimura Y, Hayashi M, Ohtaki M, Ohtani K, Shinozaki N
and Minami H: Inflammation-based prognostic markers of metastatic
pancreatic cancer using real-world data in Japan: The Tokushukai
REAl-world Data (TREAD) project. Oncol Lett. 27(136)2024.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Chen LT, Satoh T, Ryu MH, Chao Y, Kato K,
Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, et al: A phase 3 study
of nivolumab in previously treated advanced gastric or
gastroesophageal junction cancer (ATTRACTION-2): 2-year update
data. Gastric Cancer. 23:510–519. 2020.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Dovedi SJ, Adlard AL, Lipowska-Bhalla G,
McKenna C, Jones S, Cheadle EJ, Stratford IJ, Poon E, Morrow M,
Stewart R, et al: Acquired resistance to fractionated radiotherapy
can be overcome by concurrent PD-L1 blockade. Cancer Res.
74:5458–5468. 2014.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Deng L, Liang H, Burnette B, Beckett M,
Darga T, Weichselbaum RR and Fu YX: Irradiation and anti-PD-L1
treatment synergistically promote antitumor immunity in mice. Clin
Invest. 124:687–695. 2014.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Yamaguchi O, Kaira K, Hashimoto K, Mouri
A, Miura Y, Shiono A, Nishihara F, Murayama Y, Noda SE, Kato S, et
al: Radiotherapy is an independent prognostic marker of favorable
prognosis in non-small cell lung cancer patients after treatment
with the immune checkpoint inhibitor, nivolumab. Thorac Cancer.
10:992–1000. 2019.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Sharabi AB, Lim M, DeWeese TL and Drake
CG: Radiation and checkpoint blockade immunotherapy:
Radiosensitisation and potential mechanisms of synergy. Lancet
Oncol. 16:e498–e509. 2015.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Proctor MJ, Talwar D, Balmar SM, O'Reilly
DS, Foulis AK, Horgan PG, Morrison DS and McMillan DC: The
relationship between the presence and site of cancer, an
inflammation-based prognostic score and biochemical parameters.
Initial results of the Glasgow inflammation outcome study. Br J
Cancer. 103:870–876. 2010.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Proctor MJ, Morrison DS, Talwar D, Balmer
SM, O'Reilly DS, Foulis AK, Horgan PG and McMillan DC: An
inflammation-based prognostic score (mGPS) predicts cancer survival
independent of tumour site: A Glasgow inflammation outcome study.
Br J Cancer. 104:726–734. 2011.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Proctor MJ, Morrison DS, Talwar D, Balmer
SM, Fletcher CD, O'Reilly DS, Foulis AK, Horgan PG and McMillan DC:
A comparison of inflammation-based prognostic scores in patients
with cancer. A Glasgow inflammation outcome study. Eur J Cancer.
47:2633–2641. 2011.PubMed/NCBI View Article : Google Scholar
|
|
57
|
McMillan DC: The systemic
inflammation-based Glasgow prognostic score: A decade of experience
in patients with cancer. Cancer Treat Rev. 39:534–540.
2013.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Wu TH, Tsai YT, Chen KY, Yap WK and Luan
CW: Utility of high-sensitivity modified Glasgow prognostic score
in cancer prognosis: A systemic review and meta-analysis. Int J Mol
Sci. 24(1318)2023.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Wang Y, Lei Y, Zheng D, Yang Y, Luo L, Li
J and Xie X: Prognostic value of lung immune prognostic index in
non-small cell lung cancer patients receiving immune checkpoint
inhibitors: A meta-analysis. Pathol Oncol Res.
30(1611773)2024.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Carril-Ajuria L, Lavaud P, Dalban C,
Negrier S, Gravis G, Motzer RJ, Chevreau C, Tannir NM, Oudard S,
McDermott DF, et al: Validation of the lung immune prognostic index
(LIPI) as a prognostic biomarker in metastatic renal cell
carcinoma. Eur J Cancer. 204(114048)2024.PubMed/NCBI View Article : Google Scholar
|
